Title

Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older

Authors:

Patricia C. Lloyd,^a Gyanada Acharya,^b Henu Zhao,^b Nimesh Shah,^b Godwin Anguzu,^b Derick Ambarsoomzadeh,^b Tainya C. Clarke,^a Xinyi Ng,^a Mao Hu,^b Yoganand Chillarige,^b Richard A. Forshee,^a Steven A. Anderson^a

Affiliations:

^a Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States

^b Acumen, LLC, 500 Airport Blvd. Suite 100, Burlingame, CA 94010, United States

Corresponding Author:

Patricia C. Lloyd, PhD, ScM

Health Statistician

Office of Biostatistics and Pharmacovigilance

Center for Biologics Evaluation and Research

U.S. Food & Drug Administration

10903 New Hampshire Ave., Building 71

Silver Spring, MD 20993

Email: patricia.lloyd@fda.hhs.gov

Author Email Addresses:

Patricia C. Lloyd (Patricia.Lloyd@fda.hhs.gov), Gyanada Acharya (gacharya@acumenllc.com), Henu Zhao (hzhao@acumenllc.com), Nimesh Shah (nshah@acumenllc.com), Godwin Anguzu (ganguzu@acumenllc.com), Derick Ambarsoomzadeh (dericka@acumenllc.com), Tainya C. Clarke (Tainya C.), Xinyi Ng (Xinyi Ng (Xinyi.Ng@fda.hhs.gov)), Mao Hu (mhu@acumenllc.com), Yoganand Chillarige (ychillarige@acumenllc.com), Richard A. Forshee (Richard A. Forshee), Steven A. Anderson (Steven.Anderson@fda.hhs.gov).

ABSTRACT

Background

Influenza vaccination is widely recommended for individuals aged 6 months and older in the United States (U.S.). While the safety of annual influenza vaccines is well established, FDA conducts routine monitoring and evaluation of safety. This study assessed the safety of 2023-2024 influenza vaccines among elderly U.S. Medicare beneficiaries.

Methods

A self-controlled case series (SCCS) analysis compared incidence rate ratios (IRR) of anaphylaxis, encephalitis/encephalomyelitis/acute disseminated encephalomyelitis, Guillain-Barré syndrome (GBS), transverse myelitis, hemorrhagic stroke (HS), non-hemorrhagic stroke (NHS), transient ischemic attack (TIA), and NHS or TIA, following 2023-2024 seasonal influenza vaccinations in risk and control intervals among Medicare beneficiaries aged 65 years and older. We used conditional Poisson regression to estimate IRRs and 95% confidence intervals (CIs) adjusted for event-dependent observation time for certain outcomes, seasonality, and uncertainty from outcome misclassification where feasible. For health outcomes with statistically significant associations, we stratified results by concomitant vaccination status.

Results

We observed a total of 20,258,006 influenza vaccinees among the Medicare population, and no statistically significant elevations of risk for anaphylaxis, encephalitis/encephalomyelitis (with ADEM), GBS, HS, or TM. For the combined NHS/TIA outcome (22-42-day risk window), we observed a small elevation in risk that was statistically significant in both the Fee-For-Service (FFS) and Medicare Advantage (MA) populations that received a high-dose vaccine. This risk

was also statistically significant among MA beneficiaries that received any influenza vaccine. Additionally, we observed a small statistically significant risk for the individual TIA outcome (22-42-day risk window) among the MA population that received any influenza vaccine.

Conclusion

Results from this study indicate that the benefits of seasonal influenza vaccines continue to outweigh the risks. The small statistically significant increased risk of stroke outcomes observed in the study must be carefully considered in light of the known benefits of influenza vaccination.

1 INTRODUCTION

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) strongly recommends influenza vaccination annually for all individuals aged 6 months and older in the United States (U.S.), recognizing its role as a cornerstone for primary prevention against seasonal influenza. Influenza vaccines are reformulated each year to target the expected dominant circulating strains, and the U.S. Food and Drug Administration's (FDA) Vaccine and Related Biological Products Advisory Committee (VRBPAC) recommended the 2023-2024 season's vaccine composition to remain relatively consistent with the prior season.

ACIP recommended three influenza vaccines for use in people aged 65 years or older: High-dose inactivated influenza vaccines (HD-IIV4s), recombinant influenza vaccines (RIV4s), and the quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). For the 2023-2024 season, multiple IIV4s and RIV4s were available, each with age-specific guidelines (Supplemental Table 1). The Afluria, Fluarix, FluLaval, Fluzone, and Flucelvax Quadrivalent vaccines were approved for people ages 6 months and older, and the Flublok Quadrivalent vaccine was approved for people ages 18 years and older. (4, 5)

While influenza vaccines are generally considered safe based on evidence from past seasons, surveillance is useful for monitoring for potential associations with specific adverse health outcomes such as anaphylaxis, encephalitis/encephalomyelitis, Guillain-Barré syndrome (GBS), stroke, and transverse myelitis. (6,7) Safety monitoring can identify and address any emerging concerns associated with alterations in vaccine formulations, particularly considering the widespread use of influenza vaccines in the Medicare population. This includes populations with

weak immune responses to the influenza vaccine and those with pre-existing conditions, such as obesity or diabetes.⁽⁸⁾

The U.S. FDA Center for Biologics Evaluation and Research (CBER) monitors the safety of vaccines and conducted surveillance of the 2023-2024 season's influenza vaccines for several potential health outcomes. Through a collaborative agreement between FDA and the Centers for Medicare & Medicaid Services (CMS), we conducted a self-controlled case series (SCCS) study to assess the safety of the 2023–2024 seasonal influenza vaccines among Medicare beneficiaries aged 65 years and older. The primary objectives of this study were to: i) monitor influenza vaccination uptake for the 2023–2024 season and calculate observed counts and rates for outcomes of interest and ii) use the SCCS method to estimate the incidence rate ratio (IRR) and examine the association between influenza vaccination and each pre-specified health outcome, when sufficiently powered. The secondary objective of this study was to examine the effect of concomitant vaccination, when case counts allowed, on the risk of health outcomes with statistically significant associations in the primary analyses.

2 METHODS

2.1 Data Sources, Study Population, and Study Period

This study utilized administrative claims data from CMS. The CMS Medicare claims database offers comprehensive data on healthcare service usage, sourced from Medicare Shared Systems Data (SSD) for Fee-for-Service (FFS; Medicare Parts A and B, but not Part C) enrollees and the Encounter Data System (EDS) for Medicare Advantage (MA) enrollees, covering inpatient, outpatient, and pharmacy settings (Medicare Part D claims). We used the CMS Medicare

Enrollment Database (EDB) and Common Medicare Environment (CME) to capture demographic characteristics and death information, and the Minimum Data Set (MDS) 3.0 to determine nursing home residency status.

This study included individuals aged 65 years and older in the FFS and MA Medicare populations who received a 2023–2024 influenza vaccine and met eligibility criteria outlined in Supplementary Figure 1. The study start date was August 1, 2023, which aligned with the start of the 2023–2024 influenza season in the US. We had two separate study end dates for the two Medicare populations, June 29, 2024 (FFS) and August 3, 2024 (MA), to ensure adequate vaccine capture and 90% data completeness for health outcomes of interest. (9)

2.2 Exposure and Outcomes

The exposure in this study was the first influenza vaccine administration observed during the study period. Exposures for influenza vaccines (Supplemental Table 2) were identified using vaccine-specific codes, including Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), and National Drug Codes (NDCs) in the inpatient, outpatient professional, professional, or pharmacy care settings. Influenza vaccines included the HD-IIV4 and the quadrivalent aIIV4. All other vaccine types, including indication of general influenza vaccine administration, were grouped into one category.

Our study monitored eight incident outcomes: anaphylaxis, encephalitis/encephalomyelitis/acute disseminated encephalomyelitis, GBS, transverse myelitis (TM), hemorrhagic stroke (HS), non-hemorrhagic stroke (NHS), transient ischemic attack (TIA), and a composite NHS or TIA outcome (NHS/TIA). These were captured in the observation period following influenza vaccination, and identified using *International Classification of Diseases, Tenth Revision*, *Clinical Modification* codes in either primary or secondary diagnosis positions (except GBS,

which was assessed in only the primary diagnosis position) (Supplemental Table 3). To be classified as an incident outcome, a particular outcome must not have prior occurrences during a specified time period (i.e., the clean window). Additional outcome-specific exclusions were applied for HS, NHS, NHS/TIA, TIA, and TM (Supplemental Table 4).

2.3 Covariates

To characterize the study population, we defined various demographic, socioeconomic, geographic, and medical covariates. We used Medicare enrollment databases to obtain information on demographic, socioeconomic and geographic characteristics, and diagnosis or procedure codes from medical claims to identify concomitant vaccinations, immunocompromising and medical conditions. We assessed medical conditions in the 365 days prior to the influenza vaccination, and concomitant vaccinations on the same day as the influenza vaccination.

2.4 Study Design and Follow-up

We used an SCCS design to compare incident health outcomes during post-vaccination risk and control intervals, controlling for time-invariant confounders by making comparisons within, rather than between, individuals. (10) Individuals were followed for the duration of the outcomespecific observation period, starting from the date of influenza vaccination and ending 90 days thereafter for all outcomes except anaphylaxis (16 days post-vaccination). The risk interval was a period of hypothesized excess risk following vaccination and was defined for each outcome based on literature review and clinician input and has been used in several prior FDA studies. (11, 12) For our sensitivity analyses, a washout period, defined as the period between the risk and control interval, was established to avoid carryover effects from vaccination contributing to the control interval. The control interval comprised all other time in the post-vaccination observation

period not in the risk interval or washout period. The claims settings, risk and control intervals, and clean windows for each outcome are defined in Supplemental Table 3. Individuals' time intervals were censored at disenrollment, death, receipt of a subsequent influenza vaccine, end of the observation period, or the end of the study period.

2.5 Statistical Analysis

2.5.1 Descriptive Analyses

We produced descriptive summaries of vaccine recipient characteristics, vaccine uptake, and health outcomes following influenza vaccination. Additionally, we generated a demographic and medical covariate-stratified outcome summary describing vaccination counts, outcome counts, and outcome rates (per 100,000 person-years) within individual outcome cohorts.

2.5.2 Inferential Analyses

The primary SCCS analysis was conducted for individuals who received any age-appropriate influenza vaccine and estimated IRRs and 95% CIs, comparing health outcome rates in the risk and control intervals using a conditional Poisson regression. For each health outcome, Attributable Risk (AR) was calculated per 100,000 vaccinations and person-years, with a standard error estimated through bootstrap resampling. Secondary analysis was conducted only for health outcomes with a statistically significant increased IRR observed in the primary analysis and consisted of two subgroups: (1) those with an observed influenza vaccination on the same day as any prespecified concomitant vaccine, and (2) those with an observed influenza vaccination without any prespecified concomitant vaccine.^a

^a Concomitant vaccines for Medicare beneficiaries included COVID-19, PCV/PPSV, RSV, and Shingrix.

The primary and secondary analyses were adjusted for (i) event-dependent observation time for outcomes with 30-day case fatality rates (CFR) of 10 percent or higher, (ii) seasonality for all outcomes, and (iii) positive predictive value (PPV) for outcomes with available PPV from prior medical record reviews. The adjustment for event-dependent observation time, developed by Farrington et al. (herein referred to as the "Farrington adjustment"), was applied to outcomes with a CFR of 10 percent or higher, compensating for shortened observation times. (13) The CFR was calculated in the FFS SCCS study population by measuring the percentage of deaths within 30 days of an incident outcome in 2022. b To reduce potential bias from seasonal outcome patterns, we adjusted for seasonality by using incidence rates of outcomes estimated from the full Medicare population 65 years and older from corresponding calendar months in 2022-2023 as the baseline incidence of outcomes in the risk and control intervals. To address potential misclassification from claims-based outcome definitions, quantitative bias analysis with multiple imputation was performed for outcomes with available PPV estimates from prior studies (Supplemental Table 5). The PPV indicates the proportion of true cases among those verified through medical record reviews from prior vaccine safety studies. Using PPV-based multiple imputation, we addressed uncertainty from outcome misclassification by generating simulated datasets where cases were sampled with probabilities equal to the PPVs derived from prior medical record review in the FFS population. PPV-based imputation analyses could not be applied across all health outcomes because certain outcomes were not able to be included in medical record reviews and did not have available estimates from previous studies. Supplemental Table 6 presents the most adjusted primary analysis for each outcome.

^b CFR calculated in the FFS SCCS study population was also applied in analyses for the MA population

Sensitivity analyses were performed for the primary analysis. First, a washout period of 14-days between risk and control intervals (applicable for all outcomes except anaphylaxis) was added to reduce potential bias from carryover effects from vaccination contributing to control interval risk. Second, for outcomes with a case fatality rate $\geq 10\%$, the full planned observation period was credited to each individual, regardless of death or disenrollment. The Farrington adjustment was removed to evaluate potential bias stemming from violation of the SCCS assumption regarding the independence of events from observation length. (13)

All analyses were conducted using R 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria), and SAS v.9.4 (SAS Institute Inc., Cary, NC, United States). This surveillance activity was conducted as part of the FDA public health surveillance mandate, and the surveillance activities are not considered research and therefore are exempt from institutional review board review and approval.⁽¹⁴⁾

3 RESULTS

3.1 Descriptive Results

We observed a total of 20,258,006 influenza vaccinees among the Medicare population, with 12,660,709 FFS and 7,597,297 MA beneficiaries receiving a vaccine during the study period (Figures 1a and 1b). The HD-IIV4 (high-dose) vaccine accounted for about half of the total uptake in both the FFS (49.5%) and MA (54.4%) populations, while the aIIV4 (adjuvanted) vaccine was received by 41.9% and 26.8% of FFS and MA beneficiaries, respectively.

Approximately 8.6% of FFS and 18.9% of MA beneficiaries received other vaccine type.

Vaccine distribution was relatively consistent across various socio-demographic and geographical characteristics in both the FFS and MA populations (Table 1). The majority of Medicare FFS (72%) and MA (73%) vaccinated individuals were aged 65-79 years. And, in both the vaccinated FFS and MA populations, there was a higher proportion of females (~58.0%) compared to males (~42.0%). The majority of vaccinees were white (86.7% in FFS and 72.9% in MA), and majority of our study population were community-dwelling (i.e., did not reside in a nursing home) (98.0% in FFS and 98.3% in MA). We also observed concomitant vaccinations among the study population, with COVID-19 (21.8% in FFS and 0.6% in MA) and the respiratory syncytial virus (RSV) (7.0% in FFS and 0.9% in MA) being the most common vaccines administered with influenza.

Table 2 summarizes outcome counts, person-time, and incidence rates by risk and control intervals for all study outcomes. Among both the FFS and MA populations, health outcomes with the highest rates (>100 outcomes per 100,000 person-years) included the stroke outcomes, HS, NHS, NHS/TIA, and TIA.

3.2 Inferential Results

All health outcomes, except transverse myelitis in the MA population, were sufficiently powered to detect a minimum IRR of 1.2 to 3 for inferential analyses.

3.2.1 Primary Analyses

We did not observe statistically significant elevations of risk for anaphylaxis, encephalitis/encephalomyelitis (with ADEM), GBS, HS, or TM, in SCCS analyses with applicable adjustments for each health outcome (Supplemental Table 6). The results were

consistent among both the FFS and MA populations, and within persons receiving any, high-dose, or adjuvanted vaccines (Table 3, Figures 2a and 2b).

In the SCCS analyses with seasonality, PPV, and Farrington adjustments, we observed a slightly elevated risk that was statistically significant for the combined outcome of NHS/TIA among both the FFS and MA populations. The small, elevated risk was only observed in the risk window of 22-42 days after high-dose vaccine (FFS and MA). The small risk was also reflected in the MA population that received any influenza vaccine. In the FFS population, the IRR for persons receiving high-dose vaccines was 1.07 (95% CI: 1.01, 1.14). In the MA population, the IRR was 1.11 (95% CI: 1.01, 1.22) following the high-dose vaccine, and 1.10 (95% CI: 1.02, 1.17) following any influenza vaccine. The elevated risk was not observed in persons that received adjuvanted vaccines (FFS IRR: 0.99, 95% CI: 0.93, 1.07, MA IRR: 1.10, 95% CI: 0.97, 1.25) or among FFS beneficiaries that received any influenza vaccine (FFS IRR: 1.04, 95% CI: 0.99, 1.08).

The elevated risk was not consistently observed in the individual NHS or TIA outcomes. For the two NHS and TIA individual outcomes, the only statistically significant elevated risk was observed in the seasonality and PPV-adjusted analysis for TIA in the MA population (IRR: 1.12, 95% CI: 1.00, 1.25). Consistent with the combined NHS/TIA outcome, this risk for TIA was observed only in the 22-42-day risk window, and among persons vaccinated with any influenza vaccine. We also did not observe a significant risk for NHS in either of the FFS or MA populations. Among persons who received a high-dose influenza vaccine, the IRR for NHS was slightly elevated but not statistically significant in the 22-42-day risk window for FFS (IRR: 1.06 95% CI: 0.98, 1.14) and MA (IRR: 1.06, 95% CI: 0.94, 1.19) populations.

3.2.2 Secondary Analyses

We conducted secondary analyses to evaluate the risk of NHS/TIA and TIA following vaccination among those with and without concomitant vaccination. Approximately 27.5% (FFS) and 3.6% (MA) of individuals with NHS/TIA had any concomitant vaccination with the influenza vaccine. The statistically significant risk that we observed in the primary analyses was observed only among individuals without concomitant vaccines (Table 4).

For NHS/TIA in the 22-42-day risk window among FFS vaccinees without a concomitant vaccination, we observed a statistically significant risk for high-dose (IRR: 1.12, 95% CI: 1.04, 1.20), and any (IRR: 1.06, 95% CI: 1.00, 1.11) influenza vaccine. Similarly, for NHS/TIA in the 22-42-day risk window among MA vaccinees without a concomitant vaccination, we observed a statistically significant risk for high-dose (IRR: 1.11, 95% CI: 1.01, 1.22) and any (IRR: 1.10, 95% CI: 1.03, 1.18) influenza vaccine. For the individual TIA outcome in the 22-42-day risk window, and among MA vaccinees without a concomitant vaccination, we observed a statistically significant risk for any (IRR: 1.13, 95% CI: 1.01, 1.26) influenza vaccine. We did not observe statistically significant risk among individuals with concomitant vaccines.

3.2.3 Sensitivity Analyses

In our sensitivity analyses assessing a 14-day washout period between risk and control intervals, results remained consistent for all outcomes for which we did not observe significantly elevated risk in the primary analyses (Table 5). The statistically significant IRR for NHS/TIA in the 22-42-day risk window following a high-dose vaccine that was observed in the FFS (IRR: 1.06, 95% CI: 0.99, 1.14) and MA (IRR: 1.09, 95% CI: 0.98, 1.20) populations were no longer significant in the washout analysis. However, a statistically significant elevation in risk for NHS/TIA among the MA population persisted for any (IRR: 1.08, 95% CI: 1.00, 1.16) influenza

vaccine (Table 5). Finally, the small, elevated risk for the individual TIA outcome in the 22-42-day risk window was no longer significant among the MA population that received any influenza vaccine (IRR: 1.09, 95% CI: 0.97, 1.23).

We did not observe statistically significant elevations in risk for any health outcome in the full planned observation period sensitivity analyses for the FFS and MA populations (Table 6). In the FFS population, the IRR for NHS/TIA (22-42-day risk window) was 1.03 (95% CI: 0.97, 1.09) for the high-dose vaccine and 1.00 (95% CI: 0.96, 1.04) for any influenza vaccine. The corresponding IRR in the MA population was 1.07 (95% CI: 0.98, 1.17) for the high-dose vaccine, and 1.06 (95% CI: 0.99, 1.13) for any influenza vaccine.

4 DISCUSSION

In this study of approximately 20 million Medicare beneficiaries aged 65 years and older that received an annual influenza vaccine, small but statistically significant elevations in risk for NHS/TIA and TIA in the 22–42-day risk interval were observed. However, no statistically significant elevations in risk were observed for NHS/TIA and TIA in our sensitivity analyses for Medicare FFS population. In our washout sensitivity analyses, a small significant elevation in risk for TIA (22–42-day risk interval) persisted among MA beneficiaries who had received any influenza vaccine. There were no statistically significant elevations of risk for anaphylaxis, encephalitis/encephalomyelitis (with ADEM), GBS, HS, or TM, in adjusted SCCS analyses in the Medicare FFS or MA populations. In our concomitant vaccination analysis for NHS/TIA and TIA, we observed statistically significant elevations in risk among individuals who did not receive a concomitant vaccination.

While influenza vaccines are generally considered safe based on studies conducted from previous seasons, some studies have reported an increased risk of health outcomes following influenza vaccination. (6, 7, 15, 16) In a self-controlled case series study of several health outcomes following influenza vaccination among adults aged 65 years and older during three influenza seasons (2016–2017, 2017–2018 and 2018–2019), an increased stroke risk was observed following high-dose or adjuvanted influenza vaccination in the primary and age subgroup analyses, but these findings were not consistent across the three respiratory seasons. (12) During the 2023-2024 respiratory season, we identified a small yet statistically significant increase in risk; in all IRR estimates for NHS/TIA and TIA, the magnitude of the IRR was less than 1.2 which may be due to difficulty in diagnosing TIA. (17)

Our study has several strengths. First, our study was conducted in a large administrative claims database utilizing both FFS and MA beneficiaries, representing the majority of U.S adults aged 65 years and older. With more than 20 million influenza vaccine doses included in the study, our study was well-powered to identify rare health outcomes following vaccination. Second, we used a self-controlled design comparing the rate of each outcome in risk interval to the rate in control interval within each individual which enables control for time-invariant confounding. This is particularly important in our population that may experience health concerns that increase the risk for health outcomes under evaluation. Third, we incorporated adjustments to several analyses including accounting for seasonality and event-dependent observation time. Finally, when the PPV was available from prior medical record review, a PPV multiple imputation-based quantitative bias analysis helped to account for uncertainty in our IRR and AR estimates due to potential miscoding in claims data.

Our study also has several limitations for consideration. First, outcome misclassification is a concern as cases were identified using administrative claims data. However, we implemented PPV-adjusted analyses to partially address this potential misclassification. Second, the postvaccination risk and control intervals for the health outcomes may have been mis-specified, but we expect that the washout sensitivity analyses partially accounted for this limitation. The risk and control intervals were determined based on clinician consultation, but it may be difficult to determine when the rates of adverse events post-vaccination return to baseline. Third, this design does not account for time-varying confounders and does not adjust for changes over time among vaccinated individuals. However, we expect that the impact of time-varying confounding is minimal since the total follow-up time for any individual was 90 days. Finally, despite the large administrative claims database used for this study, sample size may have impacted secondary concomitant vaccination analyses or subgroup analyses when evaluating rare outcomes. Inconsistent results in the composite NHS/TIA and individual outcomes (NHS or TIA) were potentially due to insufficient statistical power in the subpopulations. With the two individual outcomes, the smaller sample size lowered statistical power to accurately detect small IRRs.

Conclusion

Through an FDA-CMS partnership, this study evaluated the safety of the 2023–2024 seasonal influenza vaccines among U.S. adults aged 65 years and older and found a small yet statistically significant increase in risk of the composite outcome of NHS/TIA and TIA following influenza vaccination. There were no statistically significant elevations in incidence rates of encephalitis/encephalomyelitis, GBS, or transverse myelitis observed to be associated with influenza vaccines. The potential risk of NHS/TIA and TIA following vaccination must be carefully considered with known benefits of influenza vaccination. Based on the results from this

study, FDA believes the benefits of seasonal influenza vaccination continue to outweigh the risks.

Funding

This work was supported by the U.S. Food and Drug Administration through the Department of Health and Human Services (HHS) Contracts [HHSF-223-2018-10020I and GS-10F-0133S], Task Orders [75F40123F19005 and 75FCMC21F0067].

Declaration of competing interest

Co-authors from U.S. Food and Drug Administration and Acumen LLC declared no conflicts of interests. The following authors reported a conflict of interest:

Acknowledgments

We thank Rose Do for her support in providing clinical insight to study findings, and Bradley Lufkin for his support with manuscript drafting and review. We appreciate review and feedback provided by Dr. Henry Zhang and Dr. Carla Zelaya on the manuscript. We thank Ms. Krista Fekecs for project support.

5 REFERENCES

- 1. Centers for Disease Control and Prevention. Key Facts About Seasonal Flu Vaccine [Available from: https://www.cdc.gov/flu/prevent/keyfacts.htm.
- 2. U.S. Food and Drug Administration. Influenza Vaccine for the 2023-2024 Season [Available from: https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2023-2024-season.
- 3. U.S. Food and Drug Administration. Influenza Vaccine for the 2022-2023 Season [Available from: https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2022-2023-season.
- 4. Centers for Disease Control and Prevention. IIS Data Code Sets [Available from: https://www.cdc.gov/vaccines/programs/iis/code-sets.html.
- 5. Centers for Disease Control and Prevention. Seasonal Flu Vaccines [Available from: https://www.cdc.gov/flu/prevent/flushot.htm.
- 6. Bart S, Kevin Cannon, Darrell Herrington, Richard Mills, Eduardo Forleo-Neto, Kelly Lindert, and Ahmed Abdul Mateen. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a phase III, double-blind, multicenter, randomized, non-inferiority study. Human vaccines & immunotherapeutics. 2016;12(no. 9):2278-88.
- 7. Chong CR, Vivian J. Park, Bevin Cohen, Michael A. Postow, Jedd D. Wolchok, and Mini Kamboj. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clinical Infectious Diseases 2020;70(no. 2):193-9.
- 8. Wiggins KB, Maria A. Smith, and Stacey Schultz-Cherry. The nature of immune responses to influenza vaccination in high-risk populations. Viruses 2021;13(no. 6):1109.
- 9. Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, Fireman BH, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011;41(2):121-8.
- 10. Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. 2016;354:i4515.
- 11. Lu Y, Matuska K, Nadimpalli G, Ma Y, Duma N, Zhang HT, et al. Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults. JAMA. 2024;331(11):938-50.
- 12. Lu Y, Matuska K, Ma Y, Laniyan L, Chillarige Y, Anderson SA, et al. Stroke After Influenza Vaccines in Older Adults in the US, 2016 to 2019. JAMA Network Open. 2024;7(7):e2423926-e.
- 13. Farrington CP, Anaya-Izquierdo K, Whitaker HJ, Hocine MN, Douglas I, Smeeth L. Self-Controlled Case Series Analysis With Event-Dependent Observation Periods. Journal of the American Statistical Association. 2011;106(494):417-26.
- 14. United States (U.S.) Department of Health and Human Services (DHHS). 45 CFR 46 Common Rule Protections for Research Subjects 2021 [Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html.
- 15. Asghar Z, Coupland C, Siriwardena N. Influenza vaccination and risk of stroke: Self-controlled case-series study. Vaccine. 2015;33(41):5458-63.
- 16. Sen A, Bakken IJ, Govatsmark RES, Varmdal T, Bønaa KH, Mukamal KJ, et al. Influenza vaccination and risk for cardiovascular events: a nationwide self-controlled case series study. BMC Cardiovascular Disorders. 2021;21(1):31.

17. Fitzpatrick T, Gocan S, Wang CQ, Hamel C, Bourgoin A, Dowlatshahi D, et al. How do neurologists diagnose transient ischemic attack: A systematic review. International Journal of Stroke. 2018;14(2):115-24.

Tables and Figures for

Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older

Table 1. Socio-demographic and Geographical Characteristics of Persons Receiving Influenza Vaccines Stratified by Vaccine Type and Medicare Plan

Characteristic	Any Influenz	a Vaccination	High-Dose Infl	uenza Vaccination	Adjuvanted Influ	uenza Vaccination	Other Influenza Vaccination	
Character istic	N	%	N	%	N	%	N	%
Total Fee-For-Service	12,660,709	100.00	6,266,613	100.00	5,306,614	100.00	1,087,482	100.00
Total Medicare Advantage	7,597,297	100.00	4,129,412	100.00	2,035,611	100.00	1,432,274	100.00
Age (Years)								
Fee-For-Service								
65-69	2,900,034	22.91	1,398,857	22.32	1,234,687	23.27	266,490	24.51
70-74	3,382,610	26.72	1,674,159	26.72	1,448,947	27.30	259,504	23.86
75-79	2,783,830	21.99	1,399,962	22.34	1,165,808	21.97	218,060	20.05
80-84	1,860,983	14.70	941,921	15.03	757,442	14.27	161,620	14.86
85-89	1,067,797	8.43	533,551	8.51	428,901	8.08	105,345	9.69
≥90	665,455	5.26	318,163	5.08	270,829	5.10	76,463	7.03
Medicare Advantage	,		,		,		,	
65-69	1,970,675	25.94	1,049,718	25.42	507,803	24.95	413,154	28.85
70-74	1,982,979	26.10	1,085,208	26.28	528,391	25.96	369,380	25.79
75-79	1,621,726	21.35	894,358	21.66	439,305	21.58	288,063	20.11
80-84	1,093,059	14.39	599,698	14.52	300,804	14.78	192,557	13.44
85-89	603,873	7.95	327,656	7.93	167,627	8.23	108,590	7.58
>90	324,985	4.28	172,774	4.18	91,681	4.50	60,530	4.23
Sex	324,703	7.20	172,774	7.10	71,001	7.50	00,550	7.23
Fee-For-Service								
	7 201 527	57.67	3,601,992	<i>57.</i> 40	2 040 050	57.44	CE1 177	50.01
Female	7,301,527	57.67	, ,	57.48	3,048,058	57.44	651,477	59.91
Male	5,359,182	42.33	2,664,621	42.52	2,258,556	42.56	436,005	40.09
Medicare Advantage	4.40.4.50.4	50.04	2 207 270	70.04	1 100 500	5 0.54	005 500	
Female	4,424,781	58.24	2,395,370	58.01	1,193,623	58.64	835,788	58.35
Male	3,172,516	41.76	1,734,042	41.99	841,988	41.36	596,486	41.65
Sex and Age (Years)								
Fee-For-Service								
Female								
65-69	1,650,513	13.04	794,671	12.68	705,139	13.29	150,703	13.86
70-74	1,899,030	15.00	939,454	14.99	810,221	15.27	149,355	13.73
75-79	1,575,553	12.44	791,439	12.63	654,574	12.34	129,540	11.91
80-84	1,070,802	8.46	539,888	8.62	432,683	8.15	98,231	9.03
85-89	647,891	5.12	320,762	5.12	259,372	4.89	67,757	6.23
≥90	457,738	3.62	215,778	3.44	186,069	3.51	55,891	5.14
Male			, , , , ,				,	
65-69	1,249,521	9.87	604,186	9.64	529,548	9.98	115,787	10.65
70-74	1,483,580	11.72	734,705	11.72	638,726	12.04	110,149	10.13
75-79	1,208,277	9.54	608,523	9.71	511,234	9.63	88,520	8.14
80-84	790,181	6.24	402,033	6.42	324,759	6.12	63,389	5.83
85-89	419,906	3.32	212,789	3.40	169,529	3.19	37,588	3.46
83-89 ≥90	207,717	3.32 1.64	102,385	1.63	84,760	1.60	20,572	1.89
-	207,717	1.04	102,383	1.03	04,700	1.00	20,372	1.69
Medicare Advantage								
Female	1 100 500	14.70	500 204	1.4.40	200 640	1.4.20	222 520	1621
65-69	1,122,582	14.78	598,394	14.49	290,649	14.28	233,539	16.31

70-74	1,133,105	14.91	618,273	14.97	303,920	14.93	210,912	14.73
75-79	946,902	12.46	519,331	12.58	258,449	12.70	169,122	11.81
80-84	637,654	8.39	347,482	8.41	176,591	8.68	113,581	7.93
85-89	366,412	4.82	197,293	4.78	102,259	5.02	66,860	4.67
≥90	218,126	2.87	114,597	2.78	61,755	3.03	41,774	2.92
Male	210,120	2.07	114,577	2.70	01,733	3.03	71,//7	2.72
65-69	848,093	11.16	451,324	10.93	217,154	10.67	179,615	12.54
70-74	849,874	11.19	466,935	11.31	224,471	11.03	158,468	11.06
75-79	674,824	8.88	375,027	9.08	180,856	8.88	118,941	8.30
80-84	455,405	5.99	252,216	6.11	124,213	6.10	78,976	5.51
85-89	237,461	3.13	130,363	3.16	65,368	3.21	41,730	2.91
					29,926			
<u>≥90</u>	106,859	1.41	58,177	1.41	29,926	1.47	18,756	1.31
Race/Ethnicity								
Fee-For-Service	20005	2.25	101.511	4.04	110.150	2.22	45.004	4.00
Asian	286,965	2.27	121,711	1.94	118,163	2.23	47,091	4.33
Black	579,565	4.58	278,316	4.44	222,609	4.19	78,640	7.23
Hispanic	124,166	0.98	55,471	0.89	45,664	0.86	23,031	2.12
American Indian/Alaskan Native	39,711	0.31	27,376	0.44	6,600	0.12	5,735	0.53
White	10,974,468	86.68	5,475,854	87.38	4,623,539	87.13	875,075	80.47
Other	254,659	2.01	116,635	1.86	110,964	2.09	27,060	2.49
Missing/Unknown	401,175	3.17	191,250	3.05	179,075	3.37	30,850	2.84
Medicare Advantage								
Asian	360,996	4.75	168,901	4.09	79,403	3.90	112,692	7.87
Black	923,951	12.16	479,786	11.62	253,942	12.47	190,223	13.28
Hispanic	311,034	4.09	139,372	3.38	69,408	3.41	102,254	7.14
American Indian/Alaskan Native	21,592	0.28	14,014	0.34	3,714	0.18	3,864	0.27
White	5,535,497	72.86	3,094,485	74.94	1,520,435	74.69	920,577	64.27
Other	245,086	3.23	131,376	3.18	59,251	2.91	54,459	3.80
Missing/Unknown	199,141	2.62	101,478	2.46	49,458	2.43	48,204	3.37
Urban/Rural	,		,		,		,	
Fee-For-Service								
Urban	10,471,719	82.71	5,089,280	81.21	4,536,562	85.49	845,877	77.78
Rural	2,186,765	17.27	1,176,309	18.77	768,988	14.49	241,468	22.20
Missing/Unknown	2,225	0.02	1,024	0.02	1,064	0.02	137	0.01
Medicare Advantage	2,223	0.02	1,021	0.02	1,001	0.02	157	0.01
Urban	6,546,856	86.17	3,546,048	85.87	1,782,899	87.59	1,217,909	85.03
Rural	1,049,849	13.82	583,069	14.12	252,559	12.41	214,221	14.96
Missing/Unknown	592	0.01	295	0.01	153	0.01	144	0.01
HHS Region*	372	0.01	2/3	0.01	133	0.01	177	0.01
Fee-For-Service								
Region 1	807,065	6.37	391,493	6.25	362,176	6.82	53,396	4.91
Region 2	1,160,259	9.16	510,381	8.14	523,026	9.86	126,852	11.66
Region 3	1,569,242	12.39	783,971	12.51	650,355	12.26 22.22	134,916	12.41
Region 4	2,550,759	20.15	1,143,897	18.25	1,179,146		227,716	20.94
Region 5	2,063,800	16.30	1,109,753	17.71	813,692	15.33	140,355	12.91
Region 6	1,264,201	9.99	702,843	11.22	420,067	7.92	141,291	12.99
Region 7	710,102	5.61	344,687	5.50	330,089	6.22	35,326	3.25
Region 8	468,966	3.70	285,968	4.56	151,014	2.85	31,984	2.94
Region 9	1,521,115	12.01	697,246	11.13	671,195	12.65	152,674	14.04
Region 10	530,222	4.19	292,634	4.67	199,534	3.76	38,054	3.50

Missing/Unknown	14,978	0.12	3,740	0.06	6,320	0.12	4,918	0.45
Medicare Advantage								
Region 1	299,991	3.95	183,220	4.44	68,721	3.38	48,050	3.35
Region 2	659,422	8.68	322,677	7.81	158,791	7.80	177,954	12.42
Region 3	687,609	9.05	405,897	9.83	140,617	6.91	141,095	9.85
Region 4	1,398,447	18.41	687,666	16.65	384,073	18.87	326,708	22.81
Region 5	1,341,244	17.65	761,688	18.45	430,630	21.15	148,926	10.40
Region 6	757,143	9.97	338,536	8.20	213,501	10.49	205,106	14.32
Region 7	271,448	3.57	165,851	4.02	81,412	4.00	24,185	1.69
Region 8	266,358	3.51	171,806	4.16	73,032	3.59	21,520	1.50
Region 9	1,505,647	19.82	861,610	20.87	375,811	18.46	268,226	18.73
Region 10	341,469	4.49	225,404	5.46	81,117	3.98	34,948	2.44
Missing/Unknown	68,519	0.90	5,057	0.12	27,906	1.37	35,556	2.48
Facility/Provider Type	06,319	0.90	3,037	0.12	27,900	1.57	33,330	2.40
Fee-For-Service								
	600 776	4.01	255 001	5.60	104 171	2.47	60.004	6.22
Hospital	608,776	4.81	355,801	5.68	184,171	3.47	68,804	6.33
Office	3,836,991	30.31	2,160,151	34.47	1,088,815	20.52	588,025	54.07
Pharmacy/Mass Immunization Center	7,632,281	60.28	3,504,720	55.93	3,913,588	73.75	213,973	19.68
Skilled Nursing Facility	205,070	1.62	59,088	0.94	46,133	0.87	99.849	9.18
		0.43				0.34	19,506	1.79
Home Health Agency	54,483		16,806	0.27	18,171		,	
Other	310,203	2.45	162,144	2.59	52,480	0.99	95,579	8.79
Missing/Unknown	12,905	0.10	7,903	0.13	3,256	0.06	1,746	0.16
Medicare Advantage	-0.4 -0.4							
Hospital	601,783	7.92	366,232	8.87	168,081	8.26	67,470	4.71
Office	6,194,230	81.53	3,395,748	82.23	1,640,826	80.61	1,157,656	80.83
Pharmacy/Mass Immunization	247,023	3.25	107,791	2.61	114,614	5.63	24,618	1.72
Center								
Skilled Nursing Facility	113,503	1.49	35,647	0.86	23,934	1.18	53,922	3.76
Home Health Agency	37,356	0.49	12,041	0.29	10,768	0.53	14,547	1.02
Other	386,900	5.09	202,014	4.89	73,946	3.63	110,940	7.75
Missing/Unknown	16,502	0.22	9,939	0.24	3,442	0.17	3,121	0.22
Nursing Home Residency								
Fee-For-Service								
Nursing Home	258,722	2.04	76,366	1.22	72,911	1.37	109,445	10.06
Non-Nursing Home	12,401,987	97.96	6,190,247	98.78	5,233,703	98.63	978,037	89.94
Medicare Advantage								
Nursing Home	128,307	1.69	42,239	1.02	28,781	1.41	57,287	4.00
Non-Nursing Home	7,468,990	98.31	4,087,173	98.98	2,006,830	98.59	1,374,987	96.00
Reason for Medicare Eligibility	.,,		.,,,,,,,,,		_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		-,,,,	
Fee-For-Service								
Aged without ESRD	11,688,227	92.32	5,792,053	92.43	4,947,713	93.24	948,461	87.22
Aged with ESRD	2,453	0.02	1,198	0.02	534	0.01	721	0.07
Disabled without ESRD	946,213	7.47	461,970	7.37	351,632	6.63	132,611	12.19
				0.03		0.03		
Disabled with ESRD	4,150	0.03	2,034		920		1,196	0.11
ESRD Only	19,666	0.16	9,358	0.15	5,815	0.11	4,493	0.41
Medicare Advantage	6.505.056	05.00	2.501.052	06.06	1 747 000	05.07	1 10 6 00 1	02.07
Aged without ESRD	6,525,956	85.90	3,591,073	86.96	1,747,902	85.87	1,186,981	82.87
Aged with ESRD	1,281	0.02	638	0.02	201	0.01	442	0.03
Disabled without ESRD	1,057,456	13.92	531,301	12.87	285,211	14.01	240,944	16.82

Disabled with ESRD	2,493	0.03	1,224	0.03	424	0.02	845	0.06
ESRD Only	10,111	0.13	5,176	0.13	1,873	0.09	3,062	0.21
Medicare-Medicaid Dual Eligibility								
Fee-For-Service								
Dual-Eligibility	1,016,142	8.03	431,167	6.88	352,253	6.64	232,722	21.40
Non-Dual-Eligibility	11,644,567	91.97	5,835,446	93.12	4,954,361	93.36	854,760	78.60
Medicare Advantage								
Dual-Eligibility	1,525,629	20.08	680,331	16.48	371,003	18.23	474,295	33.11
Non-Dual-Eligibility	6,071,668	79.92	3,449,081	83.52	1,664,608	81.77	957,979	66.89
Area Deprivation Index								
Fee-For-Service								
1-10(th)	1,664,327	13.15	754,394	12.04	792,014	14.93	117,919	10.84
11-20	1,567,324	12.38	742,553	11.85	707,289	13.33	117,482	10.80
21-30	1,636,947	12.93	806,895	12.88	716,733	13.51	113,319	10.42
31-40	1,552,555	12.26	776,106	12.38	664,653	12.52	111,796	10.28
41-50	1,397,021	11.03	711,645	11.36	577,133	10.88	108,243	9.95
51-60	1,231,266	9.73	629,375	10.04	497,036	9.37	104,855	9.64
61-70	1,088,332	8.60	556,441	8.88	428,563	8.08	103,328	9.50
71-80	936,761	7.40	481,467	7.68	352,714	6.65	102,580	9.43
81-90	779,125	6.15	400,520	6.39	280,098	5.28	98,507	9.06
91-100	480,784	3.80	243,548	3.89	165,771	3.12	71,465	6.57
Missing/Unknown	326,267	2.58	163,669	2.61	124,610	2.35	37,988	3.49
Medicare Advantage								
1-10(th)	907,090	11.94	511,620	12.39	237,861	11.68	157,609	11.00
11-20	850,112	11.19	501,764	12.15	205,843	10.11	142,505	9.95
21-30	784,219	10.32	453,491	10.98	204,283	10.04	126,445	8.83
31-40	767,536	10.10	429,586	10.40	214,146	10.52	123,804	8.64
41-50	755,123	9.94	419,845	10.17	210,047	10.32	125,231	8.74
51-60	744,366	9.80	404,678	9.80	210,718	10.35	128,970	9.00
61-70	735,973	9.69	394,594	9.56	205,841	10.11	135,538	9.46
71-80	699,914	9.21	365,375	8.85	192,285	9.45	142,254	9.93
81-90	653,872	8.61	325,155	7.87	174,744	8.58	153,973	10.75
91-100	596,688	7.85	268,040	6.49	153,202	7.53	175,446	12.25
Missing/Unknown	102,404	1.35	55,264	1.34	26,641	1.31	20,499	1.43
Concomitant Immunization								
Fee-For-Service								
Any Concomitant Immunization	4,307,970	34.03	2,208,998	35.25	1,959,483	36.93	139,489	12.83
COVID-19 Vaccine	2,756,078	21.77	1,354,188	21.61	1,329,088	25.05	72,802	6.69
Pneumococcal Vaccine	487,013	3.85	272,009	4.34	173,040	3.26	41,964	3.86
RSV Vaccine	883,897	6.98	484,040	7.72	381,863	7.20	17,994	1.65
Shingrix Vaccine	180,982	1.43	98,761	1.58	75,492	1.42	6,729	0.62
Medicare Advantage					, -	•	- / -	
Any Concomitant Immunization	169,195	2.23	88,394	2.14	62,181	3.05	18,620	1.30
COVID-19 Vaccine	45,145	0.59	22,812	0.55	19,870	0.98	2,463	0.17
Pneumococcal Vaccine	7,841	0.10	4,070	0.10	2,420	0.12	1,351	0.09
RSV Vaccine	70,009	0.92	36,008	0.87	27,314	1.34	6,687	0.47
Shingrix Vaccine	46,200	0.61	25,504	0.62	12,577	0.62	8,119	0.57

^{*}HHS Regions:
Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont Region 2: New Jersey, New York, Puerto Rico, and Virgin Islands

Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia

Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee

Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin

Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, and Texas

Region 7: Iowa, Kansas, Missouri, and Nebraska

Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming

Region 9: Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated State of Micronesia, Guam, Marshall Islands, and Republic of Palau

Region 10: Alaska, Idaho, Oregon, and Washington

Table 2. Adjusted Outcome Rates Among SCCS Analytic Population, by Risk and Control Intervals and Cohort

			Risk Int	terval	Control Interval			
Health Outcome	Cohort	Number of Outcomes	Adjusted Person- Years	Rate (95% CI)	Number of Outcomes	Adjusted Person- Years	Rate (95% CI)	
	Medicare FFS							
	Any influenza vaccine	16	64,427.77	24.83 (14.19, 40.33)	58	449,191.59	12.91 (9.80, 16.69)	
	High-dose influenza vaccine	*	31,989.23	21.88 (8.80, 45.09)	29	223,077.30	13.00 (8.71, 18.67)	
Amonhydovia	Adjuvanted influenza vaccine	*	27,000.49	29.63 (12.79, 58.38)	25	188,285.44	13.28 (8.59, 19.60)	
Anaphylaxis	Medicare Advantage							
	Any influenza vaccine	*	36,404.42	27.32 (13.10, 50.24)	45	255,034.69	17.64 (12.87, 23.61)	
	High-dose influenza vaccine	*	19,952.67	25.06 (8.14, 58.48)	24	139,045.20	17.26 (11.06, 25.68)	
	Adjuvanted influenza vaccine	*	9,845.25	30.47 (6.28, 89.05)	13	68,608.50	18.95 (10.09, 32.40)	
	Medicare FFS							
	Any influenza vaccine	142	1,260,542.16	11.26 (9.49, 13.28)	178	1,392,918.54	12.78 (10.97, 14.80)	
	High-dose influenza vaccine	71	627,965.63	11.31 (8.83, 14.26)	88	694,521.79	12.67 (10.16, 15.61)	
Encephalitis and/or Encephalomyelitis	Adjuvanted influenza vaccine	53	531,121.27	9.98 (7.47, 13.05)	71	587,524.20	12.08 (9.44, 15.24)	
(with ADEM)	Medicare Advantage							
	Any influenza vaccine	52	499,499.64	10.41 (7.77, 13.65)	76	550,627.98	13.80 (10.87, 17.28)	
	High-dose influenza vaccine	28	275,407.22	10.17 (6.76, 14.69)	41	303,914.78	13.49 (9.68, 18.30)	
	Adjuvanted influenza vaccine	14	134,688.46	10.39 (5.68, 17.44)	21	148,538.02	14.14 (8.75, 21.61)	
	Medicare FFS			, ,		-		
	Any influenza vaccine	93	1,318,301.10	7.05 (5.69, 8.64)	98	1,463,721.80	6.70 (5.44, 8.16)	
	High-dose influenza vaccine	46	654,858.20	7.02 (5.14, 9.37)	44	727,742.90	6.05 (4.39, 8.12)	
	Adjuvanted influenza vaccine	40	554,986.88	7.21 (5.15, 9.81)	46	616,876.13	7.46 (5.46, 9.95)	
Guillain-Barre Syndrome (GBS)	Medicare Advantage		ŕ	, , ,		•	, , ,	
	Any influenza vaccine	23	542,656.15	4.24 (2.69, 6.36)	35	600,031.21	5.83 (4.06, 8.11)	
	High-dose influenza vaccine	14	298,841.49	4.68 (2.56, 7.86)	21	330,789.34	6.35 (3.93, 9.70)	
	Adjuvanted influenza vaccine	*	146,632.93	2.73 (0.74, 6.98)	*	162,219.38	5.55 (2.54, 10.53)	
	Medicare FFS			, ,				
	Any influenza vaccine	1,949	1,306,238.98	149.21 (142.66, 155.98)	2,440	1,448,623.87	168.44 (161.82, 175.25	
Hemorrhagic stroke	High-dose influenza vaccine	1,029	649,181.25	158.51 (148.97, 168.50)	1,190	720,575.88	165.15 (155.89, 174.80	
	Adjuvanted influenza vaccine	697	550,205.08	126.68 (117.45, 136.44)	975	610,841.29	159.62 (149.75, 169.96	
	Medicare Advantage						, .	
	Any influenza vaccine	722	585,084.25	123.40 (114.56, 132.74)	828	646,597.38	128.05 (119.48, 137.08	
	High-dose influenza vaccine	411	321,427.67	127.87 (115.80, 140.85)	440	355,581.54	123.74 (112.45, 135.86	
	Adjuvanted influenza vaccine	179	158,618.51	112.85 (96.92, 130.65)	227	175,374.03	129.44 (113.15, 147.42	
	Medicare FFS		•			•	,	
Non-Hemorrhagic stroke	Any influenza vaccine	5,636	1,322,518.91	426.16 (415.10, 437.43)	6,589	1,467,906.74	448.87 (438.10, 459.84	
-	High-dose influenza vaccine	2,777	656,858.87	422.77 (407.19, 438.79)	3,257	729,684.54	446.36 (431.16, 461.96	

	Adjuvanted influenza vaccine	2,258	556,485.57	405.76 (389.20, 422.85)	2,629	618,348.91	425.16 (409.07, 441.73)
	Medicare Advantage			,			
	Any influenza vaccine	2,323	618,684.23	375.47 (360.36, 391.06)	2,639	684,907.98	385.31 (370.75, 400.29)
	High-dose influenza vaccine	1,211	339,357.71	356.85 (337.03, 377.53)	1,385	376,052.75	368.30 (349.16, 388.22
	Adjuvanted influenza vaccine	664	167,798.09	395.71 (366.18, 426.99)	737	185,845.25	396.57 (368.45, 426.26
	Medicare FFS		-	, , ,		•	
	Any influenza vaccine	8,965	1,322,453.20	677.91 (663.95, 692.09)	10,370	1,467,984.36	706.41 (692.88, 720.14
	High-dose influenza vaccine	4,480	656,825.04	682.07 (662.24, 702.34)	5,105	729,719.17	699.58 (680.52, 719.04
Non-Hemorrhagic stroke or Transient	Adjuvanted influenza vaccine	3,596	556,463.75	646.22 (625.27, 667.70)	4,254	618,388.39	687.92 (667.40, 708.91
ischemic attack	Medicare Advantage						
	Any influenza vaccine	3,719	618,867.23	600.94 (581.78, 620.57)	4,051	684,798.70	591.56 (573.48, 610.06
	High-dose influenza vaccine	2,012	339,457.16	592.71 (567.09, 619.19)	2,156	375,991.89	573.42 (549.47, 598.14
	Adjuvanted influenza vaccine	1,020	167,848.49	607.69 (570.97, 646.16)	1,143	185,814.94	615.13 (579.98, 651.85
	Medicare FFS						
	Any influenza vaccine	3,521	1,331,496.86	264.44 (255.78, 273.32)	3,988	1,480,427.42	269.38 (261.09, 277.87
	High-dose influenza vaccine	1,796	661,276.88	271.60 (259.18, 284.45)	1,963	735,847.63	266.77 (255.10, 278.84
Transient ischemic attack	Adjuvanted influenza vaccine	1,422	559,889.02	253.98 (240.95, 267.53)	1,695	623,213.02	271.98 (259.18, 285.24
Transient ischemic attack	Medicare Advantage						
	Any influenza vaccine	1,514	636,789.90	237.76 (225.93, 250.04)	1,502	705,328.23	212.95 (202.32, 224.00
	High-dose influenza vaccine	864	349,083.97	247.50 (231.27, 264.57)	816	387,033.12	210.83 (196.62, 225.81
	Adjuvanted influenza vaccine	390	172,703.86	225.82 (203.96, 249.38)	435	191,380.17	227.30 (206.44, 249.69
	Medicare FFS						
	Any influenza vaccine	24	1,313,021.07	1.83 (1.17, 2.72)	31	1,454,740.41	2.13 (1.45, 3.02)
Trongueso myslitic	High-dose influenza vaccine	11	652,261.62	1.69 (0.84, 3.02)	14	723,271.16	1.94 (1.06, 3.25)
	Adjuvanted influenza vaccine	11	552,759.41	1.99 (0.99, 3.56)	13	613,104.50	2.12 (1.13, 3.63)
Transverse myelitis	Medicare Advantage			·			
	Any influenza vaccine	*	296,600.56	1.69 (0.55, 3.93)	*	326,437.00	0.31 (0.01, 1.71)
	High-dose influenza vaccine	*	163,436.45	1.84 (0.38, 5.36)	*	180,066.73	0.56 (0.01, 3.09)
	Adjuvanted influenza vaccine	*	78,696.59	1.27 (0.03, 7.08)		86,648.32	N/A

Note: Values <11 are suppressed and denoted as * and counts equaling 0 are denoted as --

Table 3. Incidence Risk Ratio (IRR) and 95% CI by CMS Population and Influenza Vaccine Product, Most-Adjusted Analyses

Health Outcome	Cohort	IRR (95% CI)
	Medicare FFS	
	Any influenza vaccine	1.78 (0.79, 3.98)
	High-dose influenza vaccine	1.51 (0.43, 5.32)
Anaphylaxis	Adjuvanted influenza vaccine	2.03 (0.61, 6.68)
Anapnylaxis	Medicare Advantage	
	Any influenza vaccine	1.43 (0.52, 3.93)
	High-dose influenza vaccine	1.34 (0.30, 5.96)
	Adjuvanted influenza vaccine	1.41 (0.21, 9.30)
	Medicare FFS	
	Any influenza vaccine	0.93 (0.74, 1.18)
	High-dose influenza vaccine	0.92 (0.66, 1.29)
En and alide and/on En and alamosticia (mide ADEM)	Adjuvanted influenza vaccine	0.89 (0.61, 1.30)
Encephalitis and/or Encephalomyelitis (with ADEM)	Medicare Advantage	
	Any influenza vaccine	0.72 (0.49, 1.04)
	High-dose influenza vaccine	0.66 (0.40, 1.10)
	Adjuvanted influenza vaccine	0.76 (0.38, 1.52)
	Medicare FFS	
	Any influenza vaccine	1.10 (0.74, 1.63)
	High-dose influenza vaccine	1.22 (0.69, 2.16)
Guillain-Barre Syndrome (GBS)	Adjuvanted influenza vaccine	0.99 (0.55, 1.77)
Guinani-barre Syndronie (GBS)	Medicare Advantage	
	Any influenza vaccine	0.72 (0.34, 1.51)
	High-dose influenza vaccine	0.71 (0.27, 1.86)
	Adjuvanted influenza vaccine	0.55 (0.10, 3.09)
	Medicare FFS	
	Any influenza vaccine	0.97 (0.89, 1.05)
	High-dose influenza vaccine	1.04 (0.93, 1.17)
Hemorrhagic stroke (risk interval days 1-21)	Adjuvanted influenza vaccine	0.89 (0.77, 1.02)
Hemormagic stroke (fisk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	1.10 (0.96, 1.26)
	High-dose influenza vaccine	1.18 (0.98, 1.41)
	Adjuvanted influenza vaccine	1.11 (0.84, 1.45)
	Medicare FFS	
	Any influenza vaccine	0.94 (0.87, 1.02)
Hemorrhagic stroke (risk interval days 22-42)	High-dose influenza vaccine	0.99 (0.88, 1.11)
Tienformagie stroke (fisk interval days 22-42)	Adjuvanted influenza vaccine	0.86 (0.75, 0.98)
	Medicare Advantage	
	Any influenza vaccine	1.04 (0.91, 1.19)

	High-dose influenza vaccine	1.11 (0.93, 1.33)
	Adjuvanted influenza vaccine	0.96 (0.74, 1.26)
	Medicare FFS	
	Any influenza vaccine	1.00 (0.94, 1.06)
	High-dose influenza vaccine	0.98 (0.91, 1.07)
Non-Housenshoods stocks (side internal deep 1 21)	Adjuvanted influenza vaccine	1.01 (0.93, 1.11)
Non-Hemorrhagic stroke (risk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	1.01 (0.92, 1.11)
	High-dose influenza vaccine	1.00 (0.88, 1.13)
	Adjuvanted influenza vaccine	1.07 (0.91, 1.26)
	Medicare FFS	
	Any influenza vaccine	1.04 (0.99, 1.10)
	High-dose influenza vaccine	1.06 (0.98, 1.14)
Non-House who significant for the second state of the second seco	Adjuvanted influenza vaccine	1.03 (0.94, 1.12)
Non-Hemorrhagic stroke (risk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	1.07 (0.98, 1.16)
	High-dose influenza vaccine	1.06 (0.94, 1.19)
	Adjuvanted influenza vaccine	1.09 (0.93, 1.28)
	Medicare FFS	
	Any influenza vaccine	1.01 (0.97, 1.06)
	High-dose influenza vaccine	1.02 (0.95, 1.08)
No. However, in the last Transition to the description of the descript	Adjuvanted influenza vaccine	1.00 (0.93, 1.07)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	1.03 (0.96, 1.10)
	High-dose influenza vaccine	1.05 (0.96, 1.16)
	Adjuvanted influenza vaccine	0.99 (0.86, 1.13)
	Medicare FFS	, , ,
	Any influenza vaccine	1.04 (0.99, 1.08)
	High-dose influenza vaccine	1.07 (1.01, 1.14)
I. H.	Adjuvanted influenza vaccine	0.99 (0.93, 1.07)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	1.10 (1.02, 1.17)
	High-dose influenza vaccine	1.11 (1.01, 1.22)
	Adjuvanted influenza vaccine	1.10 (0.97, 1.25)
	Medicare FFS	
	Any influenza vaccine	0.96 (0.90, 1.03)
	High-dose influenza vaccine	0.99 (0.90, 1.09)
Transient ischemic attack (risk interval days 1-21)	Adjuvanted influenza vaccine	0.92 (0.82, 1.03)
·	Medicare Advantage	
	Any influenza vaccine	1.01 (0.90, 1.13)
	High-dose influenza vaccine	1.08 (0.93, 1.25)

	Adjuvanted influenza vaccine	0.82 (0.66, 1.03)
	Medicare FFS	
	Any influenza vaccine	0.97 (0.91, 1.05)
	High-dose influenza vaccine	1.03 (0.93, 1.14)
Transient ischemic attack (risk interval days 22-42)	Adjuvanted influenza vaccine	0.91 (0.82, 1.02)
Transient ischemic attack (fisk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	1.12 (1.00, 1.25)
	High-dose influenza vaccine	1.15 (0.99, 1.33)
	Adjuvanted influenza vaccine	1.08 (0.88, 1.33)
	Medicare FFS	
	Any influenza vaccine	0.76 (0.43, 1.33)
	High-dose influenza vaccine	0.87 (0.39, 1.96)
T	Adjuvanted influenza vaccine	0.77 (0.33, 1.83)
Transverse myelitis	Medicare Advantage	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A

Table 4. Incidence Risk Ratio (IRR) and 95% CI by CMS Population, Secondary Analyses by Concomitant Vaccination Status, Most-Adjusted Analyses

Health Outcome	Cohort	IRR (95% CI)
	Medicare FFS	
	Any influenza vaccine	
	Without concomitant vaccination	1.02 (0.97, 1.08)
	With concomitant vaccination	1.00 (0.92, 1.08)
	High-dose influenza vaccine	
	Without concomitant vaccination	1.02 (0.95, 1.10)
	With concomitant vaccination	1.00 (0.89, 1.12)
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	0.99 (0.91, 1.08)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 1-21)	With concomitant vaccination	1.02 (0.90, 1.15)
Non-Hemorrhagic stroke of Transfell (Ischemic attack (fisk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	
	Without concomitant vaccination	1.03 (0.96, 1.11)
	With concomitant vaccination	0.73 (0.41, 1.31)
	High-dose influenza vaccine	
	Without concomitant vaccination	1.07 (0.97, 1.18)
	With concomitant vaccination	0.50 (0.21, 1.20)
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	0.98 (0.85, 1.12)
	With concomitant vaccination	1.29 (0.53, 3.16)
	Medicare FFS	
	Any influenza vaccine	
	Without concomitant vaccination	1.06 (1.00, 1.11)
	With concomitant vaccination	0.98 (0.91, 1.07)
	High-dose influenza vaccine	
	Without concomitant vaccination	1.12 (1.04, 1.20)
	With concomitant vaccination	0.96 (0.85, 1.08)
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	0.99 (0.91, 1.07)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 22-42)	With concomitant vaccination	1.01 (0.89, 1.14)
voli-riemornagie stroke of Transient ischemic attack (fisk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	
	Without concomitant vaccination	1.10 (1.03, 1.18)
	With concomitant vaccination	0.97 (0.58, 1.61)
	High-dose influenza vaccine	
	Without concomitant vaccination	1.11 (1.01, 1.22)
	With concomitant vaccination	1.05 (0.56, 1.99)
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	1.10 (0.97, 1.25)
	With concomitant vaccination	0.99 (0.38, 2.57)
	Medicare FFS	
Transient in housing other lands in terms 1 days 1 01)	Any influenza vaccine	
Transient ischemic attack (risk interval days 1-21)	Without concomitant vaccination	N/A
	With concomitant vaccination	N/A

	High-dose influenza vaccine	
	Without concomitant vaccination	N/A
	With concomitant vaccination	N/A
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	N/A
	With concomitant vaccination	N/A
	Medicare Advantage	
	Any influenza vaccine	
	Without concomitant vaccination	1.02 (0.91, 1.14)
	With concomitant vaccination	0.52 (0.20, 1.35)
	High-dose influenza vaccine	
	Without concomitant vaccination	1.10 (0.95, 1.28)
	With concomitant vaccination	0.37 (0.09, 1.58)
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	0.82 (0.65, 1.03)
	With concomitant vaccination	0.94 (0.23, 3.90)
	Medicare FFS	
	Any influenza vaccine	
	Without concomitant vaccination	N/A
	With concomitant vaccination	N/A
	High-dose influenza vaccine	
	Without concomitant vaccination	N/A
	With concomitant vaccination	N/A
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	N/A
	With concomitant vaccination	N/A
Transient ischemic attack (risk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	
	Without concomitant vaccination	1.13 (1.01, 1.26)
	With concomitant vaccination	0.79 (0.35, 1.77)
	High-dose influenza vaccine	
	Without concomitant vaccination	1.16 (1.00, 1.35)
	With concomitant vaccination	0.79 (0.28, 2.25)
	Adjuvanted influenza vaccine	
	Without concomitant vaccination	1.08 (0.88, 1.34)
	With concomitant vaccination	0.97 (0.24, 3.95)
	With Concommant vaccination	0.71 (0.27, 3.73)

Table 5. Incidence Risk Ratio (IRR) and 95% CI by CMS Population, Washout Period Sensitivity Analyses, Most-Adjusted Analyses

Health Outcome	Cohort	IRR (95% CI)
	Medicare FFS	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
Anaphylaxis	Adjuvanted influenza vaccine	N/A
Anaphytaxis	Medicare Advantage	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A
	Medicare FFS	
	Any influenza vaccine	0.90 (0.70, 1.17)
	High-dose influenza vaccine	0.87 (0.61, 1.26)
Encephalitis and/or Encephalomyelitis (with ADEM)	Adjuvanted influenza vaccine	0.89 (0.58, 1.37)
Encephanus and/of Encephalomyenus (with ADEW)	Medicare Advantage	
	Any influenza vaccine	0.64 (0.43, 0.94)
	High-dose influenza vaccine	0.55 (0.32, 0.95)
	Adjuvanted influenza vaccine	0.64 (0.31, 1.31)
	Medicare FFS	
	Any influenza vaccine	0.97 (0.64, 1.48)
	High-dose influenza vaccine	1.12 (0.61, 2.06)
Guillain-Barre Syndrome (GBS)	Adjuvanted influenza vaccine	0.85 (0.46, 1.60)
Guinain-Barre Syndrome (GBS)	Medicare Advantage	
	Any influenza vaccine	0.68 (0.31, 1.51)
	High-dose influenza vaccine	0.64 (0.23, 1.74)
	Adjuvanted influenza vaccine	0.50 (0.08, 2.97)
	Medicare FFS	
	Any influenza vaccine	0.94 (0.86, 1.02)
	High-dose influenza vaccine	1.02 (0.90, 1.15)
Hemorrhagic stroke (risk interval days 1-21)	Adjuvanted influenza vaccine	0.87 (0.75, 1.00)
	Medicare Advantage	
	Any influenza vaccine	0.98 (0.85, 1.14)
	High-dose influenza vaccine	1.02 (0.84, 1.24)

	Adjuvanted influenza vaccine	1.08 (0.81, 1.44)
	Medicare FFS	
	Any influenza vaccine	0.92 (0.84, 1.00)
	High-dose influenza vaccine	0.96 (0.85, 1.09)
Hemorrhagic stroke (risk interval days 22-42)	Adjuvanted influenza vaccine	0.85 (0.74, 0.98)
Hemormagic snoke (fisk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	0.95 (0.82, 1.09)
	High-dose influenza vaccine	0.96 (0.80, 1.16)
	Adjuvanted influenza vaccine	0.96 (0.72, 1.29)
	Medicare FFS	
	Any influenza vaccine	0.98 (0.93, 1.05)
	High-dose influenza vaccine	0.97 (0.89, 1.06)
Non-Hemorrhagic stroke (risk interval days 1-21)	Adjuvanted influenza vaccine	1.00 (0.90, 1.09)
11011 Hemorriagie stroke (flok interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	0.99 (0.90, 1.10)
	High-dose influenza vaccine	0.98 (0.86, 1.12)
	Adjuvanted influenza vaccine	1.09 (0.91, 1.30)
	Medicare FFS	
	Any influenza vaccine	1.03 (0.97, 1.09)
	High-dose influenza vaccine	1.05 (0.96, 1.14)
Non-Hemorrhagic stroke (risk interval days 22-42)	Adjuvanted influenza vaccine	1.01 (0.92, 1.11)
Tion Homoringie stoke (lisk literal days 22 72)	Medicare Advantage	
	Any influenza vaccine	1.05 (0.96, 1.16)
	High-dose influenza vaccine	1.04 (0.91, 1.18)
	Adjuvanted influenza vaccine	1.11 (0.93, 1.32)
	Medicare FFS	
	Any influenza vaccine	1.00 (0.96, 1.05)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 1-21)	High-dose influenza vaccine	1.01 (0.94, 1.08)
	Adjuvanted influenza vaccine	0.99 (0.92, 1.06)
Tron Tremorningte stroke of Transient iseneinie attack (fisk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	1.00 (0.93, 1.08)
	High-dose influenza vaccine	1.03 (0.93, 1.15)

	Any influenza vaccine	1.03 (0.98, 1.08)
	High-dose influenza vaccine	1.06 (0.99, 1.14)
	Adjuvanted influenza vaccine	0.98 (0.92, 1.06)
	Medicare Advantage	
	Any influenza vaccine	1.08 (1.00, 1.16)
	High-dose influenza vaccine	1.09 (0.98, 1.20)
	Adjuvanted influenza vaccine	1.10 (0.96, 1.27)
	Medicare FFS	
	Any influenza vaccine	0.97 (0.90, 1.04)
	High-dose influenza vaccine	0.99 (0.89, 1.10)
Transient ischemic attack (risk interval days 1-21)	Adjuvanted influenza vaccine	0.92 (0.82, 1.03)
Transfert ischemic attack (fisk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	0.99 (0.88, 1.11)
	High-dose influenza vaccine	1.07 (0.91, 1.26)
	Adjuvanted influenza vaccine	0.82 (0.64, 1.04)
	Medicare FFS	
	Any influenza vaccine	0.98 (0.91, 1.05)
	High-dose influenza vaccine	1.03 (0.92, 1.14)
Transiant ischamic attack (rick interval days 22, 42)	Adjuvanted influenza vaccine	0.91 (0.81, 1.03)
Transient ischemic attack (risk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	1.09 (0.97, 1.23)
	High-dose influenza vaccine	1.14 (0.97, 1.33)
	Adjuvanted influenza vaccine	1.07 (0.86, 1.33)
	Medicare FFS	
	Any influenza vaccine	0.68 (0.37, 1.24)
	High-dose influenza vaccine	0.97 (0.39, 2.38)
—	Adjuvanted influenza vaccine	0.62 (0.25, 1.55)
Transverse myelitis	Medicare Advantage	, , , , , , , , , , , , , , , , , , , ,
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A

Table 6. Incidence Risk Ratio (IRR) and 95% CI by CMS Population, Full Planned Observation Period Sensitivity Analyses, Most-Adjusted Analyses

Health Outcome	Cohort	IRR (95% CI)
	Medicare FFS	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
Anaphylaxis	Adjuvanted influenza vaccine	N/A
Anapnyiaxis	Medicare Advantage	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A
	Medicare FFS	
	Any influenza vaccine	0.90 (0.72, 1.12)
	High-dose influenza vaccine	0.91 (0.67, 1.24)
Encephalitis and/or Encephalomyelitis (with ADEM)	Adjuvanted influenza vaccine	0.84 (0.59, 1.20)
Encephantis and of Encephanomyerius (with HEEM)	Medicare Advantage	
	Any influenza vaccine	0.74 (0.52, 1.05)
	High-dose influenza vaccine	0.73 (0.45, 1.19)
	Adjuvanted influenza vaccine	0.72 (0.36, 1.41)
	Medicare FFS	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
Guillain-Barre Syndrome (GBS)	Adjuvanted influenza vaccine	N/A
Guillan Baile Bynaionie (GBB)	Medicare Advantage	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A
	Medicare FFS	
	Any influenza vaccine	0.92 (0.85, 0.99)
	High-dose influenza vaccine	1.01 (0.91, 1.12)
Hemorrhagic stroke (risk interval days 1-21)	Adjuvanted influenza vaccine	0.80 (0.71, 0.91)
	Medicare Advantage	
	Any influenza vaccine	1.01 (0.89, 1.15)
	High-dose influenza vaccine	1.09 (0.93, 1.29)

	Adjuvanted influenza vaccine	0.95 (0.75, 1.22)
Hemorrhagic stroke (risk interval days 22-42)	Medicare FFS	
	Any influenza vaccine	0.91 (0.85, 0.98)
	High-dose influenza vaccine	0.97 (0.87, 1.07)
	Adjuvanted influenza vaccine	0.84 (0.74, 0.94)
	Medicare Advantage	
	Any influenza vaccine	1.02 (0.90, 1.15)
	High-dose influenza vaccine	1.08 (0.92, 1.28)
	Adjuvanted influenza vaccine	0.88 (0.69, 1.13)
	Medicare FFS	
	Any influenza vaccine	0.95 (0.90, 1.00)
	High-dose influenza vaccine	0.93 (0.86, 1.01)
Non-Hemorrhagic stroke (risk interval days 1-21)	Adjuvanted influenza vaccine	0.97 (0.89, 1.05)
Non-memormagic snoke (fisk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	0.97 (0.89, 1.06)
	High-dose influenza vaccine	0.96 (0.86, 1.09)
	Adjuvanted influenza vaccine	1.01 (0.86, 1.19)
	Medicare FFS	
	Any influenza vaccine	1.00 (0.95, 1.06)
	High-dose influenza vaccine	1.02 (0.94, 1.10)
Non-Hemorrhagic stroke (risk interval days 22-42)	Adjuvanted influenza vaccine	0.99 (0.91, 1.08)
11011 Homoninagie stoke (fisk interval days 22 42)	Medicare Advantage	
	Any influenza vaccine	1.03 (0.95, 1.12)
	High-dose influenza vaccine	1.02 (0.91, 1.15)
	Adjuvanted influenza vaccine	1.03 (0.88, 1.21)
	Medicare FFS	
	Any influenza vaccine	0.97 (0.93, 1.01)
	High-dose influenza vaccine	0.97 (0.91, 1.03)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 1-21)	Adjuvanted influenza vaccine	0.96 (0.90, 1.03)
11011 Hemorragic stroke of Transfert Isolicine action (115k intelval days 1-21)	Medicare Advantage	
	Any influenza vaccine	0.99 (0.92, 1.06)
	High-dose influenza vaccine	1.01 (0.92, 1.11)
	Adjuvanted influenza vaccine	0.94 (0.83, 1.08)
Non-Hemorrhagic stroke or Transient ischemic attack (risk interval days 22-42)	Medicare FFS	

	Any influenza vaccine	1.00 (0.96, 1.04)
	High-dose influenza vaccine	1.03 (0.97, 1.09)
	Adjuvanted influenza vaccine	0.96 (0.90, 1.03)
	Medicare Advantage	
	Any influenza vaccine	1.06 (0.99, 1.13)
	High-dose influenza vaccine	1.07 (0.98, 1.17)
	Adjuvanted influenza vaccine	1.05 (0.92, 1.19)
	Medicare FFS	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
T 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Adjuvanted influenza vaccine	N/A
Transient ischemic attack (risk interval days 1-21)	Medicare Advantage	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A
	Medicare FFS	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
T	Adjuvanted influenza vaccine	N/A
Transient ischemic attack (risk interval days 22-42)	Medicare Advantage	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A
	Medicare FFS	
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	N/A
Transverse myelitis	Medicare Advantage	
	-	N/A
	Any influenza vaccine	N/A
	High-dose influenza vaccine	N/A
	Adjuvanted influenza vaccine	11/12

Figure 1a. Number of Vaccinated Patients with Qualifying Influenza Vaccine by Month; Total and by Vaccine Type, Fee-For-Service (data through 6/29/2024)




Figure 1b. Number of Vaccinated Patients with Qualifying Influenza Vaccine by Month; Total and by Vaccine Type, Medicare Advantage (data through 8/2/2024)




Figure 2a. Forest Plot of Incidence Rate Ratios (95% CI) in Primary SCCS by Analysis and Vaccine Type, Fee-For-Service




Figure 2b. Forest Plot of Incidence Rate Ratios (95% CI) in Primary SCCS by Analysis and Vaccine Type, Medicare Advantage

